ArticleCanadian journal of public health = Revue canadienne de sante publique2026
Measuring the long-term impact of the COVID-19 pandemic on HPV vaccination in Quebec, Canada: A cohort study from the Canadian immunization research network.
Article in Canadian journal of public health = Revue canadienne de sante publique, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSchool-based vaccine programs in Quebec experienced significant disruptions due to the COVID-19 pandemic. Some vaccines offered in schools, such as the human papillomavirus (HPV) vaccine, continue to fall short of the 90% vaccine coverage (VC) target for the routine program. This study aims to assess temporal changes in VC for HPV, compare trends with other vaccines delivered in schools, and examine socioeconomic disparities in HPV VC.
methodsWe conducted a retrospective cohort study using data from the Quebec Immunization Registry linked with the Quebec Ministry of Education database to compare VC among students in Grades 4 and 9 between the 2019-2020 (pre-pandemic period) and the 2022-2023 school years (post-pandemic period).
resultsHPV VC ≥ 1 dose for students in Grade 4 declined in 2022-2023 (81.6%) compared with 2019-2020 (86.1%), with persistent inequalities among students living in the most deprived areas, as well as those from neighborhoods with higher proportions of immigrants or non-French/English language spoken at home. In 2022-2023, 90.7% of girls and 88.5% of boys in Grade 9 had received ≥ 1 dose of HPV vaccine. Compared with 2019-2020, VC among girls was 2 percentage points (pp) lower. No decline was observed for the hepatitis A and B vaccine in Grade 4 and the tetanus and diphtheria vaccine in Grade 9, but coverage for the Men-C-C vaccine in Grade 9 was 3.5 pp lower in 2022-2023.
conclusionThe decline in HPV VC has continued into 2022-2023, with persistent inequalities. Sustained efforts are needed to close the gap and ensure adequate protection.
Indexed as
Identifiers
42360675What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.